It is unfortunate that the data cutoff date was 10 March, so we...

  1. 95 Posts.
    lightbulb Created with Sketch. 16
    It is unfortunate that the data cutoff date was 10 March, so we are missing a month, but even so the BORR for the KEYNOTE study seems to be 13/41 or 32% and Disease control of 24/41 58%.

    It appears at mo that CAVATAK may more suited to the Yervoy trial than Keytruda, though they are different types of trial.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.